American Chemical Society-239th national meeting--Investigating new therapeutic candidates: part 1. 21-25 March 2010, San Francisco, CA, USA.
The American Chemical Society 239th National Meeting, held in San Francisco, included topics covering developments related to the chemical optimization of therapeutics. This conference report highlights selected presentations on agents under investigation for the treatment of neurological disorders, malaria, HBV and diabetes. Investigational drugs discussed include PF-4888086, PF-4778574 and SAM-531 (all Pfizer Inc), a series of spirotetrahydro-beta-carbolines from Novartis AG, a series of biaryl ether analogs from Merck & Co Inc, and PF-04620110 (Pfizer Inc/Bristol-Myers Squibb Co).
Macauley
Donald
D
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. donald.macauley@thomsonreuters.com
D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000503:physiopathology; D015195:Drug Design; D015507:Drugs, Investigational / Q000494:pharmacology*; D006509:Hepatitis B / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D008288:Malaria / Q000188:drug therapy / Q000503:physiopathology; D009422:Nervous System Diseases / Q000188:drug therapy / Q000503:physiopathology
D015507:Drugs, Investigational